ATNM Stock Overview
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Actinium Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.85 |
| 52 Week High | US$9.86 |
| 52 Week Low | US$4.00 |
| Beta | 0.076 |
| 1 Month Change | -20.35% |
| 3 Month Change | 36.45% |
| 1 Year Change | -26.34% |
| 3 Year Change | -12.52% |
| 5 Year Change | -21.94% |
| Change since IPO | -92.39% |
Recent News & Updates
Shareholder Returns
| ATNM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.9% | -4.7% | -3.7% |
| 1Y | -26.3% | -2.7% | 20.2% |
Return vs Industry: ATNM underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: ATNM underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| ATNM volatility | |
|---|---|
| ATNM Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ATNM's share price has been volatile over the past 3 months.
Volatility Over Time: ATNM's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 49 | Sandesh Seth | www.actiniumpharma.com |
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA.
Actinium Pharmaceuticals, Inc. Fundamentals Summary
| ATNM fundamental statistics | |
|---|---|
| Market cap | US$196.07m |
| Earnings (TTM) | -US$48.82m |
| Revenue (TTM) | US$81.00k |
2,486x
P/S Ratio-4.1x
P/E RatioIs ATNM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATNM income statement (TTM) | |
|---|---|
| Revenue | US$81.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$81.00k |
| Other Expenses | US$48.90m |
| Earnings | -US$48.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.66 |
| Gross Margin | 100.00% |
| Net Profit Margin | -60,269.14% |
| Debt/Equity Ratio | 0% |
How did ATNM perform over the long term?
See historical performance and comparison